F-star Therapeutics to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference
CAMBRIDGE, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™) antibodies, today announces that Eliot Forster, Chief Executive Officer, will be presenting at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14, 2020.
Event: F-star Therapeutics Presentation
Time: 3:30 PM ET | 8:30 PM BST
Webcast Link: https://hcwevents.com
The Company will also be available for one to one meetings during the conference, September 14-16.
About F-star Therapeutics Ltd
F-star is a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit www.f-star.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005542/en/
For further information, please contact:
For investor enquiries
VP Investor Relations & Communications
+1 240 543 7970
For media enquiries
Consilium Strategic Communications
Chris Gardner, Sue Stuart, David Daley
Tel: +44 (0)20 3709 5700
Source: F-star Therapeutics Ltd.
View this news release online at: